AVEO down 4% on mid-stage tivozanib data in kidney cancer [Seeking Alpha]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Seeking Alpha
AVEO Oncology ( AVEO ) is down out of the gate this morning following the presentation of Phase 1b/2 data at ESMO on FOTIVDA (tivozanib), combined with Bristol-Myers Squibb's ( BMY ) OPDIVO (nivolumab), in patients with advanced/metastatic renal cell carcinoma (RCC). The objective response rate (ORR) was 56% (n=14/25) in patients who had received at least one prior line of therapy, including one complete responder. The disease control rate (responders + stable cancer) was 96% (n=24/25). Most patients showed cancer control for at least 48 weeks. 72% (n=18/25) experienced tumor shrinkage at least 25%. In the CheckMate-214 study, the overall survival at year 1 for Opdivo + Yervoy was 80% and 75% at 1.5 years. The ORR was 42% including a 9% complete response rate. Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). It is designed to optimize VEGF blockade while minimizing toxic side effects. #ESMO See
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- The Galien Foundation Announces 2024 Prix Galien International Awards Nominees [Yahoo! Finance]Yahoo! Finance
- Alexandria Real Estate's Q1 FFO rises on stronger occupancy rates [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Curious about Bristol Myers (BMY) Q1 Performance? Explore Wall Street Estimates for Key Metrics [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers, Cellares ink $380M CAR-T therapies supply deal [Seeking Alpha]Seeking Alpha
BMY
Earnings
- 2/2/24 - Beat
BMY
Sec Filings
- 4/22/24 - Form DEFA14A
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- BMY's page on the SEC website